文献速递妇科

贝伐珠单抗在卵巢癌靶向治疗时代的系统综述与荟萃分析

The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2021-02-02

该系统综述与荟萃分析检索2010年至2020年3月的2期和3期临床试验,评估贝伐珠单抗联合方案在晚期上皮性卵巢癌中的肿瘤学结局与毒性。一线治疗中,贝伐珠单抗联合化疗较单纯化疗显著改善无进展生存(合并HR=0.72,95%CI 0.65-0.81),但总生存无显著获益(合并HR=0.88,95%CI 0.72-1.06);复发治疗中,贝伐珠单抗联合方案显示显著的无进展生存和总生存获益。

要点

  • 一线治疗中贝伐珠单抗联合化疗显著改善PFS(HR=0.72),但OS无显著获益。
  • 复发治疗中贝伐珠单抗联合方案显示显著PFS(HR=0.52)和OS(HR=0.88)获益。
  • 肠穿孔发生率低,为1.24%(范围0-4.2%)。

核心结论

  • 含贝伐珠单抗方案在晚期和复发性上皮性卵巢癌中与显著的无进展生存获益相关。
  • 一线治疗中总生存差异未达统计学显著性,但复发治疗中贝伐珠单抗与生存改善相关。

研究设计与样本

  • 系统综述与荟萃分析,检索2010年至2020年3月期间关于晚期上皮性卵巢癌贝伐珠单抗联合治疗的2期和3期临床试验。

主要发现

  • 一线治疗中,贝伐珠单抗联合化疗较单纯化疗显著改善无进展生存(合并HR=0.72,95%CI 0.65-0.81)。
  • 一线治疗中,贝伐珠单抗联合化疗较单纯化疗总生存无显著获益(合并HR=0.88,95%CI 0.72-1.06)。
  • 复发治疗中,贝伐珠单抗联合方案较非贝伐珠单抗方案显示显著无进展生存获益(合并HR=0.52,95%CI 0.47-0.58)。
  • 复发治疗中,贝伐珠单抗联合方案较非贝伐珠单抗方案显示显著总生存获益(合并HR=0.88,95%CI 0.79-0.99)。
  • 肠穿孔发生率为1.24%(范围0-4.2%)。

关键数值与推荐

  • 一线治疗无进展生存合并HR=0.72(95%CI 0.65-0.81)。
  • 一线治疗总生存合并HR=0.88(95%CI 0.72-1.06)。
  • 复发治疗无进展生存合并HR=0.52(95%CI 0.47-0.58)。
  • 复发治疗总生存合并HR=0.88(95%CI 0.79-0.99)。
  • 肠穿孔发生率1.24%(范围0-4.2%)。

临床怎么用

  • 对于晚期上皮性卵巢癌患者,一线治疗中可考虑贝伐珠单抗联合化疗以改善无进展生存。
  • 对于复发性上皮性卵巢癌患者,贝伐珠单抗联合方案可带来无进展生存和总生存获益。
  • 使用贝伐珠单抗时需注意肠穿孔风险,但发生率较低。

局限性

  • 仅8项研究纳入定量合成,可能限制合并分析的把握度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The optimal systemic therapy strategy for advanced epithelial ovarian cancer (EOC) remains unclear. We performed a systematic review and meta-analysis to assess oncologic outcomes and toxicity of bevacizumab combination treatment in advanced EOC. METHODS: We conducted an electronic search of all phase 2 and 3 clinical trials involving bevacizumab combination therapy in advanced-stage EOC between 2010 and March 2020, using Embase, Medline, Epub Ahead of Print, Cochrane for clinical trials, Cochrane Database of Systematic Reviews, Web of Science and clinicaltrials.gov databases. Progression-free survival (PFS), overall survival (OS), and their hazard ratios (HR) when available were extracted. Pooled HR were calculated for each efficacy endpoint in the meta-analysis using inverse variance weighted method. Bias was assessed using the Cochrane Collaboration Risk of Bias I (ROB1) tool for randomized controlled trials. RESULTS: Thirty-five studies were included in the qualitative analysis and eight studies in the quantitative synthesis. In the first-line setting, bevacizumab combined with chemotherapy revealed a significant improvement in PFS (pooled HR = 0.72, 95% CI 0.65-0.81) when compared to chemotherapy alone but no significant OS benefit (pooled HR = 0.88, 95% CI 0.72-1.06). In the recurrent setting, bevacizumab combinations showed significant PFS (pooled HR = 0.52, 95% CI 0.47-0.58) and OS benefits (pooled HR = 0.88, 95% CI 0.79-0.99) compared with non-bevacizumab regimens. Rate of bowel perforation was low at 1.24% (range 0-4.2%). CONCLUSIONS: Bevacizumab-containing regimens are associated with significant PFS benefit in advanced and recurrent epithelial ovarian cancer. While the difference in OS did not reach statistical significance in the first-line setting, bevacizumab was associated with improved survival in the recurrent setting.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Liu S, Kasherman L, Fazelzad R, et al. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2021. PMID: 33546867. doi:10.1016/j.ygyno.2021.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。